Course details
HFSA 2017 Comprehensive Heart Failure Review Course & Update
YOU WILL GET THE COURSE VIA LIFETIME DOWNLOAD LINK (FAST SPEED) AFTER PAYMENT
Description:
Event Summary
We look forward to seeing you at the 2017 HFSA Review Course on October 12-15, 2017 at the Scottsdale Marriott at McDowell Mountains in Scottsdale, AZ. Please take some time to review the information below to help maximize your conference experience.
Summary
The 2017 Comprehensive Heart Failure Review Course builds upon HFSA’s successful 2015 Review and 2016 Board Review Courses by incorporating results of new research studies, increasing focus on practical management recommendations, addressing issues encountered in practice, adding case studies, and providing breakout sessions in areas of special interest.
Learning Objectives
At the conclusion of this educational activity, participants will be able to:
- Describe the epidemiology of heart failure and implement strategies for the prevention of heart failure.
- Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms.
- Assess and track the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
- Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents and non-pharmacologic options, such as diet and exercise; and implantable devices.
- Apply appropriate care strategies for patients with pulmonary hypertension, RV failure, heart failure with preserved ejection fraction, cardiorenal syndrome, peripartum and infiltrative myopathies.
- Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression.
- Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care.
- Describe characteristics of optimal candidates for cardiac transplantation or mechanical circulatory support.
- Apply strategies for atrial and ventricular arrhythmia management.
- Practice effectively in the context of health care reform and merit-based incentives
+ Topics/Speaker:
B1-1 – Assessment of Patient with New Onset HF
B1-2 – Practical Application of Risk Prediction Models
B1-3 – Sleep Disordered Breathing
B2-1 – Tricks of the Trade Challenges of RAAS Inhibition
B2-2 – Advanced Hemodynamic Modeling
B3-1 – How to Set Up a HF Clinic and Diastolic HF Program
B3-2 – How to Setup a Remote Monitoring Program
B4-1 – Having the Discussion ‐ How to Make the Conversation Easier
B4-2 – Practical Use of Biomarkers in the Clinical Setting
B4-3 – Transplant VAD Case Review
S1-1 – Models and Mechanisms of HFrEF and HFpEF
S1-2 – New Guidelines Update
S1-3 – ARNI’s and Ivabradine
S1-4 – Emerging Therapies for Chronic HF
S1-5 – HFpEF Natural History and Contemporary Management
S1-6 – Case Based Discussion
S2-1 – Natural History & Patient Assessment
S2-2 – Vasodilators & Inotropes What’s New and What Works
S2-3 – Acute HF Congestion, Cardiorenal Syndrome and Diuretic Resistance
S2-4 – Diuretics in Hospitalized patients Current Controversies and Emerging Therapies
S2-5 – Case Based Discussion
S3-1 – Patient Assessment and Classification
S3-2 – Treating PAH in the Contemporary Era
S3-3 – Pulmonary Hypertension and Left HF
S3-4 – Right HF
S3-5 – Case Based Discussion
S4-1 – Biomarker 2017 Update What’s Hot, What’s Not
S4-2 – Invasive and Non‐Invasive Hemodynamic Devices
S4-3 – Remote Monitoring Smart Phones to Telehealth
S5-1 – Clinical Variability within INTERMACS Profile I
S5-2 – Hemodynamics of Cardiogenic Shock and Devices
S5-3 – Percutaneous Devices and ECMO
S5-4 – Q&A
S6-1 – Defining Advanced HF
S6-2 – Heart Transplant Patient Selection
S6-3 – Heart Transplant ‐ Clinical Outcomes and Management
S6-4 – LVAD Patient Selection and Clinical Outcomes
S6-5 – LVAD Adverse Events and Patient Management
S6-6 – Managing Drug Interactions
S6-7 – Q&A
S7-2 – Cardiac Resynchronization Therapy ‐ Recent Advances
S7-3 – Arrhythmia Management Antiarrhythmic Drugs and VT Ablation
S7-4 – Impact of AFIB on HF
S7-5 – Systemic Anticoagulation from VKA to NOAC
S7-6 – Prevention of Sudden Cardiac Death , Wearables and Implantables
S7-7 – Q&A
S8-1 – Reducing 30‐Day Readmissions
S8-2 – Transitioning Patients Out of the Hospital
S8-3 – Strategies for Keeping Patients out of the Hospital
S8-4 – They Are Not Ready for Palliative Care Really Then When
S8-5 – Case Based Discussion
S9-1 – Hypertrophic Cardiomyopathies and Screening for Sudden Cardiac Death
S9-2 – Cardiac Amyloidosis
S9-3 – Pregnancy and Peripartum Cardiomyopathy
S9-4 – Inflammatory Cardiomyopathies & Myocarditis
S9-5 – Metabolic Challenges Obesity, Diabetes, Anemia
S9-6 – Fireside Chat with Patient
S9-7 – Q&A
